Order Online! Now! Get your $50 coupon for online order.Order Online! Now! Get your $50 coupon for online order.
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD9-H5222 | Human | Human CD69 / CLEC2C Protein, His Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Decitabine/Cedazuridine | ASTX-727-LD; ASTX-727-10; E-7727/decitabine; Decitabine/E7727; ASTX-727 | Approved | Astex Pharmaceuticals Inc, National Cancer Institute | INAQOVI, Inaqovi, Inqovi | United States | Myelodysplastic Syndromes | Otsuka Pharmaceutical Co Ltd | 2020-07-07 | Leukemia, Myelogenous, Chronic; Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Leukemia, Myeloid, Acute; Glioma; Nervous System Neoplasms; Neurilemmoma | Details |
Triclabendazole | EGA-230B; CGA-89317; NVP-EGA230 | Approved | Novartis Pharma Ag | Egaten, Fasinex, Triclathera | Iran | Fascioliasis | Novartis Pharma Ag | 1989-01-01 | Fascioliasis | Details |
Mecobalamin | E-0302 | Approved | Myelogen, Naso B12, NASOCOBAL, Methycobal, 弥尔神, 悦敏兴, RHINOCOBAL, 奇信, 曲力, 弥可保 | Peripheral Nervous System Diseases; Autistic Disorder; Neuritis; Neuralgia; Vitamin B 12 Deficiency; Amyotrophic Lateral Sclerosis; Fibromyalgia | Details | |||||
Decitabine | 5-aza-CdR; NSC-127716; AzadC; E-7373; DAC | Approved | Eisai Co Ltd | Dacogen, 达珂 | Mainland China | Myelodysplastic Syndromes | Mgi Pharma Inc | 2006-05-02 | Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vulvar Neoplasms; Lymphoma, Mantle-Cell; Neuroblastoma; Breast Neoplasms; Lymphoma, Follicular; Colorectal Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lung Neoplasms; Multiple Myeloma; Lymphoma; Thyroid Neoplasms; Anemia, Sickle Cell; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Precancerous Conditions; Breast Neoplasms, Male; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leukemia; Purpura, Thrombocytopenic, Idiopathic; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Thalassemia; Neutropenia; Esophageal Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Accelerated Phase; Myeloproliferative Disorders; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung | Details |
Azacitidine | 5-aza-CR; CC-486; NS-17; U-18496; NEX-18; NEX-18a; NSC-102816 | Approved | Celgene Corp | 维达莎, Vidaza, Onureg | United States | Myelodysplastic Syndromes | Bristol-Myers Squibb Company | 2004-05-19 | Leukemia, Myeloid, Acute; Immune System Diseases; Brain Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Tuberculosis, Pulmonary; Prostatic Neoplasms; Breast Neoplasms; Osteosarcoma; Sarcoma; Primary Myelofibrosis; Hepatic Insufficiency; Multiple Myeloma; Leukemia, Myelomonocytic, Juvenile; Lymphoma, Non-Hodgkin; Lymphoma; Thyroid Neoplasms; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Large Granular Lymphocytic; Carcinoma, Non-Small-Cell Lung; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelogenous, Chronic; Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Solid tumours; Leukemia, Myeloid; Ependymoma; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Leukemia; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Nasopharyngeal Neoplasms; Glioblastoma; Small Cell Lung Carcino | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Curcumin | VOLT-03; VOLT-3; NSC-32982 | Phase 3 Clinical | University Of Pennsylvania | Lymphoma, T-Cell, Cutaneous; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tobacco Use Disorder; Oral Submucous Fibrosis; Prostatic Neoplasms; Breast Neoplasms; Pancytopenia; Cognitive Dysfunction; Neuralgia; Colorectal Neoplasms; Dentist-Patient Relations; Cervical Intraepithelial Neoplasia; Uterine Cervical Dysplasia; Cigarette Smoking; Asthma; Primary Myelofibrosis; Urinary Incontinence, Urge; Adenocarcinoma, Mucinous; Lung Neoplasms; Lichen Planus, Oral; Renal Insufficiency, Chronic; Osteoarthritis; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Adenocarcinoma; Aortic Aneurysm, Abdominal; Uterine Cervical Neoplasms; Stomatitis; Neoplasm Metastasis; Macular Degeneration; Thrombocythemia, Essential; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Primary Dysautonomias; Drug-Related Side Effects and Adverse Reactions; Hyperemia; Non-radiographic axial spondyloarthritis; Optic Atrophy, Hereditary, Leber; Depression; Gastritis, Atrophic; Rectal Neoplasms; Non-alcoholic Fatty Liver Disease; Dia | Details |
NTX-301 | NTX-303 | Phase 1 Clinical | Southern Research Institute, Pinotbio Inc | Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Glioma; Leukemia, Myeloid, Acute | Details |
Decitabine/Tetrahydrouridine | EPI-01 | Phase 2 Clinical | Epicdestiny | Anemia, Sickle Cell | Details |
Fluorocyclopentenylcytosine | FCPEC; RX-3117; TV-1360; PCS-3117; RX 3117 | Phase 2 Clinical | Rexahn Pharmaceuticals Inc | Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms | Details |
Azacitidine/Cedazuridine | ASTX-030 | Phase 3 Clinical | Otsuka Pharmaceutical Co Ltd | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
FdCyd | NSC-48006; Ro-5-1090 | Phase 2 Clinical | City Of Hope National Medical Center, National Cancer Institute | Head and Neck Neoplasms; Esophageal Neoplasms; Neoplasms; Myelodysplastic Syndromes; Urinary Bladder Neoplasms; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
EF-009 | EF-009 | Phase 2 Clinical | Everfront Biotech Co Ltd | Pancreatic Neoplasms | Details |
Guadecitabine Sodium | S-110; 0RB89YH367 (UNII code); SGI-110 | Phase 3 Clinical | Otsuka Holdings Co Ltd | Klatskin Tumor; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Paraganglioma; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Cholangiocarcinoma; Chondrosarcoma; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Myeloproliferative Disorders; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Kidney Neoplasms; Ovarian Neoplasms | Details |
This web search service is supported by Google Inc.